Huard Geneviève, Bilodeau Marc
Liver Unit, Hôpital Saint-Luc, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada H2X 3J4.
Int J Hepatol. 2012;2012:672986. doi: 10.1155/2012/672986. Epub 2012 Jun 20.
Non-neoplastic portal vein thrombosis (PVT) is an increasingly recognized complication of liver cirrhosis. It is often diagnosed fortuitously and can be either partial or complete. The clinical significance of PVT is not obvious except in some situations such as when patients are on the waiting list for liver transplantation. The only known therapy is anticoagulation which has been shown to permit the disappearance of thrombosis and to prevent further extension. Anticoagulation is a challenging therapy in individuals with liver cirrhosis because of the well-recognized coagulation abnormalities observed in that setting and because of the increased risk of bleeding, especially from gastrointestinal tract caused by portal hypertension. We herein review the current knowledge on that topic in order to highlight the advantages and disadvantages of the currently proposed therapeutic attitudes in face of the diagnosis of PVT in individuals with cirrhosis.
非肿瘤性门静脉血栓形成（PVT）是肝硬化一种日益被认识到的并发症。它常常是偶然被诊断出来的，可为部分性或完全性。PVT的临床意义除了在某些情况下（如患者在等待肝移植名单上时）并不明显。唯一已知的治疗方法是抗凝，已证明抗凝可使血栓消失并防止进一步扩展。抗凝对于肝硬化患者是一种具有挑战性的治疗方法，因为在这种情况下存在公认的凝血异常，且出血风险增加，尤其是由门静脉高压引起的胃肠道出血。我们在此回顾关于该主题的当前知识，以突出面对肝硬化患者诊断为PVT时当前所提出的治疗态度的优缺点。
